Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placental Mesenchymal Stem Cell–Derived Exosomes for Severe COVID-19
IRCT20200413047063N2Phase 2Completed
- Sponsor
- Omid Cell and Tissue Processing
- Start
- Mar 2021
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-arm trial of placental mesenchymal stem cell-derived exosomes in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS), sponsored by Omid Cell and Tissue Processing. Started Mar 2021; status: completed.
02
Drugs
placental mesenchymal stem cell-derived exosomes
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on IRCT20200413047063N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200413047063N2.